AgeneBio Receives Grant from Alzheimer’s Drug Discovery Foundation for Drug-Discovery Program to Delay the Onset of Alzheimer’s Dementia

Novel GABAA program targets hippocampal overactivity that leads to neurodegeneration and cognitive decline in Alzheimer’s disease patients Baltimore, MD, June 28, 2017 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the Company has received an additional $750,000 grant from the Alzheimer’s Drug Discovery Foundation (ADDF). The grant…